Sigmoid Pharma Limited - Product Pipeline Review - 2014

Published: Oct, 2014 | Pages: 34 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Sigmoid Pharma Limited - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Sigmoid Pharma Limited - Product Pipeline Review - 2014', provides an overview of the Sigmoid Pharma Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Sigmoid Pharma Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Sigmoid Pharma Limited including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Sigmoid Pharma Limited's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Sigmoid Pharma Limited's pipeline products

Reasons to buy

- Evaluate Sigmoid Pharma Limited's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Sigmoid Pharma Limited in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Sigmoid Pharma Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Sigmoid Pharma Limited and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Sigmoid Pharma Limited
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Sigmoid Pharma Limited and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Sigmoid Pharma Limited Snapshot 5
Sigmoid Pharma Limited Overview 5
Key Information 5
Key Facts 5
Sigmoid Pharma Limited - Research and Development Overview 6
Key Therapeutic Areas 6
Sigmoid Pharma Limited - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Combination Treatment Modalities 10
Sigmoid Pharma Limited - Pipeline Products Glance 11
Sigmoid Pharma Limited - Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
Phase I Products/Combination Treatment Modalities 12
Sigmoid Pharma Limited - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Discovery Products/Combination Treatment Modalities 14
Sigmoid Pharma Limited - Drug Profiles 15
cyclosporine CR 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
cyclosporine 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
cyclosporine IR 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
cyclosporine IR + cyclosporine CR 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
calcitonin 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
dimethyloxalylglycine 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
helicobacter pylori vaccine [Hel-305] (multivalent) 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
celecoxib 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Drugs for Gastrointestinal and Immunological Disorders 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Drugs to Agonize FXR for Undisclosed Indication 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Small Molecules for Undisclosed Indication 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Sigmoid Pharma Limited - Pipeline Analysis 26
Sigmoid Pharma Limited - Pipeline Products by Target 26
Sigmoid Pharma Limited - Pipeline Products by Route of Administration 27
Sigmoid Pharma Limited - Pipeline Products by Molecule Type 28
Sigmoid Pharma Limited - Pipeline Products by Mechanism of Action 29
Sigmoid Pharma Limited - Recent Pipeline Updates 30
Sigmoid Pharma Limited - Dormant Projects 31
Sigmoid Pharma Limited - Locations And Subsidiaries 32
Head Office 32
Appendix 33
Methodology 33
Coverage 33
Secondary Research 33
Primary Research 33
Expert Panel Validation 33
Contact Us 34
Disclaimer 34

List of Tables
Sigmoid Pharma Limited, Key Information 5
Sigmoid Pharma Limited, Key Facts 5
Sigmoid Pharma Limited - Pipeline by Indication, 2014 7
Sigmoid Pharma Limited - Pipeline by Stage of Development, 2014 8
Sigmoid Pharma Limited - Monotherapy Products in Pipeline, 2014 9
Sigmoid Pharma Limited - Combination Treatment Modalities in Pipeline, 2014 10
Sigmoid Pharma Limited - Phase II, 2014 11
Sigmoid Pharma Limited - Phase I, 2014 12
Sigmoid Pharma Limited - Preclinical, 2014 13
Sigmoid Pharma Limited - Discovery, 2014 14
Sigmoid Pharma Limited - Pipeline by Target, 2014 26
Sigmoid Pharma Limited - Pipeline by Route of Administration, 2014 27
Sigmoid Pharma Limited - Pipeline by Molecule Type, 2014 28
Sigmoid Pharma Limited - Pipeline Products by Mechanism of Action, 2014 29
Sigmoid Pharma Limited - Recent Pipeline Updates, 2014 30
Sigmoid Pharma Limited - Dormant Developmental Projects,2014 31